Clinical Information

The Viveve Treatment has been used to treat hundreds of patients worldwide. The safety and efficacy of the procedure has been demonstrated in two clinical studies conducted in the United States and Japan1. Viveve continues to build on its strong safety and efficacy data by continuing to conduct clinical studies around the world.

Two Viveve clinical studies conducted in the United States and Japan have been published in the Journal of Sexual Medicine and the Journal of Women’s Health. Results analyzed from both the U.S. and Japan Studies showed statistically significant improvement in vaginal tightness, to pre-childbirth levels, at one, three, six, and twelve months following treatment. At 12 months, improved and sustained tightness was shown by 88% of the women. Significant improvement in sexual satisfaction was indicated through 12 month follow-up. No serious adverse events were reported in either study.

The Viveve Treatment Restored Vaginal Tightness to Pre-Childbirth Levels

VIV_Web_Charts_US VIV_Web_Charts_Japan

The Viveve study conducted in the United States was published in the Journal of Sexual Medicine in September, 2010. Successful results were reported, in the publication, at 1, 3, and 6 months, the last assessment point prior to this publication.

The second Viveve clinical study was conducted in Japan and completed in early 2012. The 12 month follow-up data was published in the Journal of Women’s Health in 2013.

Initial studies were also conducted to demonstrate the Viveve System’s radio frequency mechanism of action, how it works and the impact on vaginal tissue.

Publication of clinical study results and data continue to be accepted in peer-reviewed medical journals and international conference proceedings. Abstracts, posters, and presentations submitted to and presented at major OB/GYN and Sexual Medicine association conferences around the world can be viewed in the following category tabs.

1Includes clinical patients from the U.S. and Japan, plus an estimate of patient treated commercially based on feedback provided from physician customers as of September, 31, 2014.